Pasar al contenido principal

CANNABIDIOL COMO ACELERADOR DE LA RESPUESTA FARMACOLOGICA ANTIDEPRESIVA: UNA VIA HACIA LA IDENTIFICACION DE LOS MECANISMOS CELULARES IMPLICADOS EN LA DEPRESION.

SAF2015-67457-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD DE CANTABRIA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Autoradiographic Visualization of G Protein-Coupled Receptors in Brain

  • Vidal, Rebeca
  • Pilar-Cuéllar, Fuencisla
  • Díaz, Álvaro
  • Castro, Elena
In this chapter, two in vitro techniques applied to study the anatomical localization of a receptor are revised: firstly, the receptor-binding assay in sections, a technique to assess the location and distribution of a receptor in the tissue (descriptive and anatomical information), and secondly, the [35S]GTPγS-binding assay also in tissue slices, which allows the quantification of the level of G-protein activation by a specific GPCR´s agonist. The latter technique provides additional information about the coupling efficacy of a receptor to G-proteins (functional autoradiography), thus enabling the study of the first step in the intracellular signaling pathway after the receptor activation. Both techniques are basically performed for the in vitro autoradiographic visualization of receptors in tissue slices obtained from animal or human postmortem samples., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-67457-R MINECO/FEDER) (MINECO/FEDER, UE), the Ministry of Science, Innovation and Universities (RTI2018-097534-B-I00) (MCIU/AEI/ FEDER,UE), and the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Radioligand Binding Detection of Receptors in Brain Membranes

  • Pilar-Cuéllar, Fuencisla
  • Garro-Martínez, Emilio
  • Castro, Elena
  • Díaz, Álvaro
Transmitters, hormones, and most of the therapeutic drugs exert their biological functions by generating signals in target cells through interaction with a receptor molecule in the cellular membrane, cytosol, or even at the nucleus of the cell. Because receptors play such a crucial role in cell function, especially within the central nervous system (CNS), we need lab techniques to measure their expression and functionality. There are techniques to determine regulatory changes in receptor number (receptor density), subcellular distribution, anatomical distribution, the physiological function of the receptors as well as the ligand affinity. Here, we describe a classic method in which cells or tissue membranes are exposed to radiolabeled molecules (radioligands) that bind selectively to the receptors in the sample (receptor binding assay). Similarly, the functional consequence of the receptor occupancy or level of G protein activation can be measured by [35S]GTPγS binding assay, also known as functional binding. This assay measures the binding of the nonhydrolyzable analog [35S]GTPγS ([35S]guanosine-5′-O-(3-thio) triphosphate) to Gα subunits. The above radiometric assays are useful to determine the affinity and receptor density of a drug, and to differentiate among agonist, antagonist, and inverse agonist activities, the traditional pharmacological parameters of potency and efficacy, as well as receptor constitutive activity. Moreover, radioligand binding assays provide a powerful tool for screening drug candidates for many receptors in drug discovery research., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2015-67457-R MINECO/FEDER) (MINECO/FEDER, UE), the Ministry of Science, Innovation and Universities (RTI2018-097534-B-I00) (MCIU/AEI/FEDER,UE), and the Instituto de Salud Carlos III.